Warnings mark a first for FDA about OTC topicals rendered unapproved due to labeling for STI treatment and latest action to ...
The long-acting injectable was superior to daily oral therapy at viral suppression in treatment-experienced patients who had ...
HHS' attorney said professional organizations cannot challenge the ACIP member appointments because no final agency action ...
Novo will not submit its Ozempic/Wegovy/Rybelsus franchise and AstraZeneca refused to enter its Calquence into the 340B ...
ArriVent’s firmonertinib failed against chemo on PFS in NSCLC with exon 20 insertion mutations, but the firm also has the EGFR inhibitor in Phase III for the larger PACC mutation subpopulation.
A bipartisan Senate bill that would end the Trump Administration’s 340B rebate model pilot and create a national claims ...
Kevin Lobo announced plans to step down as Stryker's CEO after 14 years in the role and 15 with the company, during which the ...
‘Worse Performance Than Previously Disclosed’ Prompts Class I Recall Of BD Alaris Infusion Pump Sets
The FDA has classified BD’s recall of certain Alaris Pump Infusion Sets as Class I after testing found the sets can perform worse than previously disclosed, potentially causing under- or over-infusion ...
The National Institute of Allergy and Infectious Diseases also is weighing whether to participate in trials involving ...
The National Institute of Allergy and Infectious Diseases also is weighing whether to participate in trials involving vaccination schedules as the Trump Administration continues pushing to overhaul ...
BridgeBio’s timeline expects to launch infigratinib for achondroplasia sooner than expected in early 2027 after it was granted a priority review and February action date by the FDA.
CNS drug development has long presented significant challenges. Diseases can be severe and chronic, diagnoses may take years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results